144 related articles for article (PubMed ID: 20415689)
1. Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes.
Parkner T; Dyrskog SE; Laursen T; Chen JW; Mouritzen U; Brondsted L; Hermansen K; Lauritzen T; Christiansen JS
Diabetes Obes Metab; 2010 May; 12(5):414-20. PubMed ID: 20415689
[TBL] [Abstract][Full Text] [Related]
2. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
McSorley PT; Bell PM; Jacobsen LV; Kristensen A; Lindholm A
Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
[TBL] [Abstract][Full Text] [Related]
3. Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.
Ejskjaer N; Rasmussen M; Kamp N; Lindholm A; Christiansen JS
Diabetes Obes Metab; 2003 Nov; 5(6):438-45. PubMed ID: 14617230
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
Heise T; Eckers U; Kanc K; Nielsen JN; Nosek L
Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
6. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
8. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes.
McNally PG; Dean JD; Morris AD; Wilkinson PD; Compion G; Heller SR
Diabetes Care; 2007 May; 30(5):1044-8. PubMed ID: 17277042
[TBL] [Abstract][Full Text] [Related]
9. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
Dashora U; Ashwell SG; Home PD
Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
[TBL] [Abstract][Full Text] [Related]
10. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
Kann PH; Wascher T; Zackova V; Moeller J; Medding J; Szocs A; Mokan M; Mrevlje F; Regulski M
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):527-32. PubMed ID: 17115351
[TBL] [Abstract][Full Text] [Related]
11. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.
Cucinotta D; Smirnova O; Christiansen JS; Kanc K; le Devehat C; Wojciechowska M; López de la Torre M; Liebl A
Diabetes Obes Metab; 2009 Jul; 11(7):700-8. PubMed ID: 19476479
[TBL] [Abstract][Full Text] [Related]
12. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
Bott S; Tusek C; Heinemann L; Friberg HH; Heise T
Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):545-50. PubMed ID: 16235159
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes.
Bolli GB; Luzio S; Marzotti S; Porcellati F; Sert-Langeron C; Charbonnel B; Zair Y; Owens DR
Diabetes Obes Metab; 2011 Mar; 13(3):251-7. PubMed ID: 21205115
[TBL] [Abstract][Full Text] [Related]
15. Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy.
Heise T; Heinemann L; Hövelmann U; Brauns B; Nosek L; Haahr HL; Olsen KJ
Diabetes Care; 2009 Aug; 32(8):1431-3. PubMed ID: 19487640
[TBL] [Abstract][Full Text] [Related]
16. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
Kvapil M; Swatko A; Hilberg C; Shestakova M
Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
18. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
[TBL] [Abstract][Full Text] [Related]
19. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
20. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
